SAN FRANCISCO / Mar 14, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision was made at a special meeting of the board of directors on Wednesday evening, March 13, 2024. Further, as previously... Read More

One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes SAN FRANCISCO / Mar 05, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine’s (ACLM)... Read More

Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention SAN FRANCISCO / Mar 04, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day... Read More

Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path towards a potential second indication SAN FRANCISCO / Feb 20, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today... Read More

Agreement is an important step towards securing broad coverage SAN FRANCISCO / Feb 06, 2024 / Business Wire / Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation’s leading Pharmacy Benefit Managers (PBMs) negotiating on behalf of over 70 million lives... Read More

Over a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost Study suggests that using AspyreRx can empower patients to better manage their diabetes, with the potential to reduce long-term complications SAN FRANCISCO / Jan 17, 2024 / Business Wire / Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in... Read More

SAN FRANCISCO / Jan 02, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its novel PDT designed to treat metabolic dysfunction-associated steatotic liver disease (MASLD) and... Read More

Savings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes SAN FRANCISCO / Nov 28, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today disclosed several initiatives aimed at extending the company's cash runway sufficiently to demonstrate commercial... Read More

Better Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way in the North American diabetes digital behavioral therapeutics industry SAN FRANCISCO / Nov 14, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics... Read More

Company obtained FDA authorization for AspyreRx TM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO / Nov 09, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the third quarter... Read More

SAN FRANCISCO / Nov 08, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday, November 09, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on... Read More

Company to showcase AspyreRx™ Company to host sponsored education session on Tuesday, October 31, 2023; A novel approach to treating type 2 diabetes SAN FRANCISCO / Oct 26, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM)... Read More

AspyreRx is the first FDA-authorized digital behavioral therapeutic device delivering cognitive behavioral therapy for the treatment of a cardiometabolic disease As previously reported, adding AspyreRx to standard of care resulted in significant and durable reductions in A1c as well as improvements in a host of other health measures Healthcare providers in the U.S. can now begin prescribing AspyreRx SAN FRANCISCO / Oct 16,... Read More

Pivotal trial established use of AspyreRx alongside standard of care demonstrating clinically meaningful and statistically significant reduction in HbA1c leading to FDA authorization In a subgroup analysis, the use of AspyreRx and GLP-1 receptor agonists showed substantially greater A1c reductions than the previously reported results of the entire trial population Recent draft guidance from the FDA indicates the intent to... Read More

Authors conclude the totality of positive efficacy, safety and usability data indicates the potential of Better Therapeutics’ digitally delivered Cognitive Behavioral Therapy to help address the significant unmet clinical needs observed in MASLD and MASH Company expects to submit request to the FDA for Breakthrough Device Designation in Q4 2023 SAN FRANCISCO / Oct 05, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ:... Read More

1,000 participants enrolled across two studies, and six sites Studies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilization SAN FRANCISCO / Sep 28, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has completed the enrollment of 1,000... Read More

Obtained FDA Authorization for AspyreRx TM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET SAN FRANCISCO / Aug 09, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital... Read More

SAN FRANCISCO / Aug 02, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on... Read More

SAN FRANCISCO / Jul 25, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19. In addition, the Company entered into a definitive purchase agreement for the purchase and sale of 2,897,654 shares of its common... Read More

First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and webcast on July 11 at 8:30 a.m. ET SAN FRANCISCO / Jul 10, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer... Read More

Naim Alkhouri, MD, FAASLD, to Present Findings from Non-alcohol Related Fatty Liver Disease Feasibility Study SAN FRANCISCO / Jun 16, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced the... Read More

On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO / May 11, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT)... Read More

SAN FRANCISCO / May 04, 2023 / Business Wire / Better Therapeutics, Inc . ( NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Management... Read More

SAN FRANCISCO / Apr 06, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced a private placement of 7,878,786 shares of the Company's common stock at a price of $0.825 per share, which was the... Read More

Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results from exploratory trial for fatty liver disease Announced restructuring and other cost saving actions to extend financial runway Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO / Mar 30, 2023 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital... Read More

SAN FRANCISCO / Mar 23, 2023 / Business Wire / Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its fourth quarter and full year 2022 financial results before the market opens on Thursday, March 30,... Read More